Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Risk / Reward
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(103)
•••
Comment by G1945Von May 07, 2024 2:35pm
51 Views
Post# 36027283

RE:Risk / Reward

RE:Risk / Reward
goldtech wrote: So in about 5 weeks from now we will see that PMN310 has no Aria-E and can dose up to 40mg, with significant blood barrier payloads. Now the end of the road for us will be in 6 months of phase 1B where we will show selectivity to oligomers and the percentage of efficacy in stopping the propagation of toxicity. This will lead to big pharma arriving in drives with their check books and ultimate offers on the table. The risk of course is that this has no cognitive effect and the years of science is wrong, but don't forget the primates that proved otherwise. 


"So in about 5 weeks from now we will see that PMN310 has no Aria-E and can dose up to 40mg, with significant blood barrier payloads."

Phase 1a is 5-dose ascending, all safety and not Aria-E related.

G1945V

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities